Neelima Denduluri

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Metastatic Colorectal Cancer

Neoadjuvant Chemotherapy

Top Venues

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia R White, Victoria S Blinder, Jared C Foster, Laleh Amiri-Kordestani, E Shelley Hwang, Judith M Bliss, Eileen Rakovitch, Jane Perlmutter, Patricia A Spears, Elizabeth Frank, Nadine M Tung, Anthony D Elias, David A Cameron, Neelima Denduluri, Ana F Best, Andrea Gombos, Lawrence Baizer, Lynn Pearson Butler, Elena Schwartz, Eric P Winer, Larissa A Korde
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Larissa A Korde, Mark R Somerfield, Lisa Anne Carey, Jennie R Crews, Neelima Denduluri, E Shelley Hwang, Seema Ahsan Khan, Sibylle Loibl, Elizabeth A Morris, Alejandra Perez, Meredith M Regan, Patricia A Spears, Preeti K Sudheendra, William Fraser Symmans, Rachel L Yung, Brittany E Harvey, Dawn L Hershman
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (13) (2021)
Judith E Carroll, Brent J Small, Danielle B Tometich, Wanting Zhai, Xingtao Zhou, George Luta, Tim A Ahles, Andrew J Saykin, Kelly N H Nudelman, Jonathan D Clapp, Heather S Jim, Paul B Jacobsen, Arti Hurria, Deena Graham, Brenna C McDonald, Neelima Denduluri, Martine Extermann, Claudine Isaacs, Asma A Dilawari, James Root, Robert A Stern, Jeanne S Mandelblatt, null null
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype. Cancer 125 (24) (2019)
Jeanne S Mandelblatt, Wanting Zhai, Jaeil Ahn, Brent J Small, Tim A Ahles, Judith E Carroll, Neelima Denduluri, Asma Dilawari, Martine Extermann, Deena Graham, Arti Hurria, Claudine Isaacs, Paul B Jacobsen, Heather S L Jim, George Luta, Brenna C McDonald, Sunita J Patel, James C Root, Andrew J Saykin, Danielle B Tometich, Xingtao Zhou, Harvey J Cohen
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study. Cancer 126 (6) (2019)